Multinuclear biologically active Ru, Rh, Os and Ir arene complexes

Štarha, Pavel

doi:10.1016/j.ccr.2020.213690

Cited by 31 publications

(15 citation statements)

References 227 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IR spectra of the complexes 1-3 are shown in Figures S12-S14. 1 H and 13 C NMR spectra were recorded on a Bruker Ascend 500 instrument (Bruker Corporation, Billerica, MA, USA) operating at room temperature (500 MHz for 1 H and 125 MHz for 13 C); solvent residual peaks were used as internal standards.…”

Section: Spectral Methods and Elemental Analysismentioning

confidence: 99%

See 1 more Smart Citation

Synthesis and Structural Characterization of Half-Sandwich Arene–Ruthenium(II) Complexes with Bis(imidazol-1-yl)methane, Imidazole and Benzimidazole

et al. 2021

View full text Add to dashboard Cite

Mono- and binuclear arene–ruthenium(II) complexes with imidazole-containing ligands were prepared by the reaction of the ligands (L1 = bis(imidazole-1-yl)methane; ImH = 1H-Imidazole; BImH = 1H-Benzimidazole) with [(p-cym)Ru(µ-Cl)2]2 dimers. When bis(imidazole-1-yl)methane reacted with [(p-cym)Ru(µ-Cl)2]2 in methanol, a binuclear complex of the type [Ru2(L1)2(p-cym)2Cl2]Cl2 (2) with cyclic structure was synthesized, whereas by using acetonitrile as a solvent under the same reaction conditions, an unexpected C–N bond cleavage was observed, and a complex of formula [Ru(ImH)2(p-cym)Cl]Cl (1) with coordinated imidazole molecules was obtained. Another type of arene–ruthenium complex [Ru(BImH)(p-cym)Cl2] (3) was obtained by the reaction of benzimidazole and [(p-cym)Ru(µ-Cl)2]2. All compounds were characterized by spectral (FT-IR, NMR 1H, 13C) and single-crystal X-ray diffraction methods; their catalytic activity in transfer hydrogenation and the cytotoxicity against MCF-7 and HepG2 cells were evaluated.

show abstract

Section: Spectral Methods and Elemental Analysismentioning

confidence: 99%

“…Ruthenium complexes are of interest as catalysts, and they have also emerged as promising nonplatinum antitumor or antimetastatic agents [1][2][3][4][5][6]. A great number of ruthenium complexes with potential antitumor activity have been developed to date.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Structural Characterization of Half-Sandwich Arene–Ruthenium(II) Complexes with Bis(imidazol-1-yl)methane, Imidazole and Benzimidazole

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For example, Re(I), Ru(II), and Ir(III) complexes have been intensively explored as fluorescent or luminescent probes for DNA, proteins, and organelles, and some of them have displayed promising anticancer activities. 21,22 Besides, the gadolinium complexes [Gd(DTPA)(H 2 O)] 2− (Magnevist) and [Gd(DOTA) (H 2 O)] − (Dotarem) are commonly administrated as magnetic resonance imaging (MRI) contrast agents in the clinic (Fig. 1).…”

Section: Guangyu Zhumentioning

confidence: 99%

“…Actually, half-sandwich Os(II) complexes have been found to display considerable cytotoxicity as anticancer agents. 22,106 Despite their structural similarity to Ru(II) complexes, Os(II) complexes displayed a different mode of action and induced oxidative stress. Thus, it is promising to combine Os(II) with Pt(II) or Pt(IV) centers into a single molecule to improve the anticancer efficacy of Pt-based drugs.…”

Section: Summary and Perspectivesmentioning

confidence: 99%

Platinum-containing heterometallic complexes in cancer therapy: advances and perspectives

Zhu

2022

Inorg. Chem. Front.

View full text Add to dashboard Cite

show abstract

“…Among them, Ru(II) metallacycles have been successfully applied for the chemotherapeutic or phototherapeutic treatment of cancer 24 – 28 . Noteworthy, Ru(II) metallacycles can selectively enter cancer cells with a long-term stay compared to normal cells 29 , 30 . More importantly, the emission/excitation wavelength and phototherapy efficiency of metallacycles could be finely regulated by embedding well-designed fluorescent ligands without tedious chemical synthesis 31 – 34 .…”

Section: Introductionmentioning

confidence: 99%

Construction of emissive ruthenium(II) metallacycle over 1000 nm wavelength for in vivo biomedical applications

et al. 2022

Nat Commun

View full text Add to dashboard Cite

Although Ru(II)-based agents are expected to be promising candidates for substituting Pt-drug, their in vivo biomedical applications are still limited by the short excitation/emission wavelengths and unsatisfactory therapeutic efficiency. Herein, we rationally design a Ru(II) metallacycle with excitation at 808 nm and emission over 1000 nm, namely Ru1085, which holds deep optical penetration (up to 6 mm) and enhanced chemo-phototherapy activity. In vitro studies indicate that Ru1085 exhibits prominent cell uptake and desirable anticancer capability against various cancer cell lines, especially for cisplatin-resistant A549 cells. Further studies reveal Ru1085 induces mitochondria-mediated apoptosis along with S and G2/M phase cell cycle arrest. Finally, Ru1085 shows precise NIR-II fluorescence imaging guided and long-term monitored chemo-phototherapy against A549 tumor with minimal side effects. We envision that the design of long-wavelength emissive metallacycle will offer emerging opportunities of metal-based agents for in vivo biomedical applications.

show abstract

Multinuclear biologically active Ru, Rh, Os and Ir arene complexes

Cited by 31 publications

References 227 publications

Synthesis and Structural Characterization of Half-Sandwich Arene–Ruthenium(II) Complexes with Bis(imidazol-1-yl)methane, Imidazole and Benzimidazole

Synthesis and Structural Characterization of Half-Sandwich Arene–Ruthenium(II) Complexes with Bis(imidazol-1-yl)methane, Imidazole and Benzimidazole

Platinum-containing heterometallic complexes in cancer therapy: advances and perspectives

Construction of emissive ruthenium(II) metallacycle over 1000 nm wavelength for in vivo biomedical applications

Contact Info

Product

Resources

About